
    
      This open-label, non-comparative, extension trial will enroll subjects with genetically
      confirmed PMD who have completed the End-of-Study Visit in the SPIMM-202 trial. Subjects who
      do not discontinue or withdraw from the trial will receive treatment with 40 mg SC
      elamipretide for the shortest of the following: 260 weeks; regulatory approval and commercial
      availability of elamipretide in the subject's respective country; or termination of the
      clinical development for elamipretide in subjects with PMD.
    
  